- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
The Research and Development team of Ahmedabad-based Intas Pharmaceuticals has developed a COVID-19 specific Hyperimmune Globulin as treatment for patients suffering from moderate to severe
infection. According to a press release published in CISION, Hyperimmune Globulin can also be employed as prophylaxis for frontline workers who come in close contact with COVID-19 patients.
The new treatment could serve as a useful therapeutic technique against the viral disease until a vaccine becomes available. Intas is among the world's first pharmaceutical firms to
adopt this approach towards the treatment of COVID-19. The Drug Controller General of India (DCGI) has granted approval for the conduction of clinical trials for the newly developed
Hyperimmune Globulin. Once its efficacy and safety are established in the trials, the product will be available for the treatment of COVID-19 patients. This therapeutic innovation will be
part of the company’s Corporate Social Responsibility (CSR) initiative. The firm will collaborate with Indian blood banks for the development of the treatment technique, which will enable
the procurement of convalescent plasma (plasma extracted from patients recovered from COVID-19 infection).
